Bogutai®Teriparatide Injection
Bogutai® (Teriparatide Injection), developed by Uni-Bio Science Group, received market approval from the China NMPA on January 16, 2024, as the first domestically produced teriparatide formulation in a pre-filled pen injector for the treatment of osteoporosis.
Bogutai® is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture. The treatment significantly reduces the risk of vertebral and non-vertebral fractures; however, its effect on hip fractures has not been established.
20 μg : 80 μL, 2.4 mL per syringe
Product Features
Stimulates new bone formation, significantly increases bone density, and improves bone quality.
Demonstrates a significant reduction in vertebral and non-vertebral fracture risks.
Interrupts the fracture cascade effect, reducing the risk of subsequent fractures following an initial osteoporotic fracture.
Product Advantages
-
As the first domestic biosimilar, it offers ease of use and excellent efficacy. -
Demonstrates therapeutic equivalence to the reference product with a favorable safety profile. -
Serves as a first-line treatment option for osteoporosis patients at very high fracture risk.
More Products
-
Bogutai®Teriparatide InjectionBogutai® is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture.
-
GeneTime®Human Epidermal Growth Factor Derivative for External Use, LiquidGeneTime® is indicated for burn wounds (including superficial and deep second-degree burns), residual small wounds, various chronic ulcers (including vascular, radiation-induced, and diabetic ulcers), and fresh skin graft donor sites.
-
GeneSoft®Human Epidermal Growth Factor(ARI Extended Type) Eye DropsCorneal epithelial defects of various etiologies, including corneal mechanical trauma, postoperative states of corneal procedures, mild dry eye disease accompanied by superficial punctate keratopathy, and mild chemical burns.
